切换至 "中华医学电子期刊资源库"
高级检索
中华细胞与干细胞杂志(电子版)

中华细胞与干细胞杂志(电子版) ›› 2020, Vol. 10 ›› Issue (01) : 20 -25. doi: 10.3877/cmj.j.issn.2095-1221.2020.01.004

所属专题： 文献；

论著

肿瘤坏死因子-α促进乳腺癌转移的分子机制研究
徐瑞1, 邱彤璐1, 梅杰2, 沈书凝1, 朱一超3,†()   
  1. 1. 211166　南京医科大学生理学系
    2. 211166　南京医科大学生理学系；214023　无锡，南京医科大学附属无锡人民医院肿瘤科
    3. 211166　南京医科大学生理学系；211166　南京医科大学生殖医学国家重点实验室
  • 收稿日期:2019-05-08 出版日期:2020-02-01
  • 通信作者: 朱一超

The mechanism of tumor necrosis factor-α in promoting breast cancer metastasis

Rui Xu1, Tonglu Qiu1, Jie Mei2, Shuning Shen1, Yichao Zhu3,†()   

  1. 1. Department of Physiology, Nanjing Medical University, Nanjing 211166, China
    2. Department of Physiology, Nanjing Medical University, Nanjing 211166, China;Department of Oncology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi 214023, China
    3. Department of Physiology, Nanjing Medical University, Nanjing 211166, China;State Key Laboratory of Reproductive Medicine, Nanjing Medical University, Nanjing 211166, China
  • Received:2019-05-08 Published:2020-02-01
  • Corresponding author: Yichao Zhu
  • About author:
    Corresponding author:ZhuYichao, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

徐瑞, 邱彤璐, 梅杰, 沈书凝, 朱一超. 肿瘤坏死因子-α促进乳腺癌转移的分子机制研究[J/OL]. 中华细胞与干细胞杂志(电子版), 2020, 10(01): 20-25.

Rui Xu, Tonglu Qiu, Jie Mei, Shuning Shen, Yichao Zhu. The mechanism of tumor necrosis factor-α in promoting breast cancer metastasis[J/OL]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2020, 10(01): 20-25.

目的

探究肿瘤坏死因子-α （TNF-α）促进乳腺癌转移的分子机制。

方法

采集病理学确诊为乳腺癌的患者血液标本53例，首先把MDA-MB-231乳腺癌细胞分为对照组、TNF-α诱导组，再把乳腺癌细胞分为空载对照组（转染空载体）、Arf6-T27N组（转染Arf6-T27N）、空载转染+TNF-α组（转染空载体后加500 ng/ml TNF-α）、Arf6-T27N+TNF-α组（转染Arf6-T27N后加500 ng/ml TNF-α）。采用酶联免疫检测法（ELISA）对乳腺癌患者血浆中TNF-α含量进行检测，采用划痕实验检测细胞的迁移能力，采用小G蛋白活化实验（GLISA）筛选并检测对照组和TNF-α诱导组的小G蛋白及其诱导效应。两组间比较采用t检验，多组间比较采用单因素方差分析，两两比较采用LSD检验；采用χ2检验或Fisher确切概率法分析TNF-α表达高低与临床病理参数的关系。

结果

与未发生淋巴结转移的乳腺癌患者比较，已发生淋巴结转移的患者血浆中TNF-α的含量（391.24±307.35比709.58±277.51）升高，差异具有统计学意义（P < 0.001）；与对照组比较，TNF-α诱导组乳腺癌细胞相对愈合面积（1.00±0.04比2.34±0.25）增大，细胞小G蛋白Arf6活性（1.00±0.02比3.11±0.14）升高，差异有统计学意义（P均< 0.001）；与空载转染+TNF-α组比较，Arf6-T27N+TNF-α组乳腺癌细胞的迁移能力（2.33±0.14比1.83±0.15）降低，差异具有统计学意义（P < 0.001）。

结论

本研究阐明TNF-α通过激活Arf6促进乳腺癌细胞迁移，提示TNF-α/Arf6可作为控制乳腺癌转移的新靶点。

关键词: TNF-α, Arf6, 乳腺癌, 淋巴结转移
Objective

Tumor necrosis factor-α (TNF-α) , as one of the inflammatory factors, plays an important role in the oncogenesis and development of tumors. This study aimed to explore the mechanism of TNF-α in promoting breast cancer metastasis.

Methods

Plasma TNF-α levels of 53 breast cancer patients were detected by enzyme-linked immunosorbent assay (ELISA) . The migration ability of MDA-MB-231 breast cancer cells treated with vehicle, TNF-α, transfected with vector, Arf6-T27N, vectorplus TNF-α, Arf6-T27N plus TNF-α was detected by wound healing assay. TNF-α-induced activization of small G proteins of MDA-MB-231 cells treated with vehicle or TNF-α was screened and detected by small G protein activation assay (GLISA) . The comparison of means between the two groups was performed using t-test. The comparison of means between multiple groups was performed using a one-way analysis of variance, and the LSD test was used in the post hoc comparisons. The relationships between the levels of TNF-α and clinicopathological parameters were analyzed by χ2 test or Fisher exact probability method.

Results

Compared with breast cancer patients without lymph node metastasis, the plasma levels of TNF-α in patients with lymph node metastasis were significantly increased (709.58±277.51 vs 391.24±307.35, P< 0.001) .Wound healing assay showed that TNF-α could significantly promote the migration of MDA-MB-231 cells compared to the control cells (2.34±0.25 vs 1.00±0.04, P< 0.001) . TNF-α notably activatedthe small G protein Arf6 compared to the control group (3.11±0.14 vs 1.00±0.02, P< 0.001) , and overexpressed Arf6 (Arf6-T27N) significantly inhibited TNF-α-induced migration of breast cancer cells compared to theTNF-α-treatedcells (1.83±0.15 vs 2.33±0.14, P< 0.001) .

Conclusion

This study demonstrates that TNF-α promotes breast cancer cell migration by activating Arf6, suggesting that TNF-α/Arf6 might be used as a new target for controlling breast cancer metastasis.

Key words: TNF-α, Arf6, Breast cancer, Lymph node metastasis
表1 血浆TNF-α表达量与乳腺癌病理参数间的关系
临床病理参数 例数 TNF-α表达量 χ2 P值
低表达 高表达
年龄       0.016 0.901
≤60岁 29 14 15    
> 60岁 24 12 12
大小       0.212 0.646
≤2 cm 33 17 16    
>2 cm 20 9 11
淋巴结转移     9.294 0.002
N0 34 22 12    
N1-3 19 4 15
远端转移     - 0.491*
M0 51 26 25    
M1 2 0 2
临床分期     1.072 0.503
1-2 44 23 21    
3-4 9 3 6
ER表达状态     3.592 0.058
阴性 12 3 9    
阳性 41 23 18
PR表达状态     0.774 0.379
阴性 13 5 8    
阳性 40 21 19
HER2表达状态     0.040 0.842
阴性 17 8 9    
阳性 36 18 18
表2 不同淋巴结转移状态的乳腺癌患者血浆TNF-α表达量
淋巴结转移 例数 TNF-α表达量
未发生 34 391.24±307.35
已发生 19 709.58±277.51
t值   3.740
P值   < 0.001
图1 正置明视场显微镜下观察两组乳腺癌细胞迁移能力（×10）
表3 TNF-α对常见小G蛋白活化程度的影响（±s，n = 3）
小G蛋白 相对活化程度 t值 P值
对照组 诱导组
Rac1 1.00±0.04 1.03±0.06 0.737 0.502
Rac2 1.03±0.07 0.93±0.13 0.122 0.909
Rac3 1.00±0.02 0.98±0.66 0.505 0.640
RhoA 1.00±0.03 0.98±0.13 0.044 0.967
Cdc42 0.98±0.06 1.00±0.12 0.216 0.840
Arf1 1.00±0.04 1.00±0.05 0.100 0.925
Arf6 1.00±0.02 3.11±0.14 25.720 < 0.001
RalA 0.97±0.09 1.00±0.07 0.441 0.682
图2 正置明视场显微镜下观察不同分组乳腺癌细胞的迁移能力（×10）
表4 不同TNF-α浓度对乳腺癌细胞中Arf6活化程度的影响（±s，n = 3）
分组 Arf6相对活化程度
对照组 1.00±0.02
100 ng/ml诱导组 1.13±0.11
500 ng/ml诱导组 3.17±0.23ab
1000 ng/ml诱导组 3.12±0.10a
F值 230.276
P值 < 0.001
表5 不同分组乳腺癌细胞的Arf6相对活化程度及迁移能力（±s，n = 3）
分组 Arf6相对活化程度 相对愈合面积
空载对照组 1.00±0.02 1.00±0.03
Arf6-T27N组 1.00±0.05 1.03±0.11
空载转染+TNF-α组 2.95±0.23a 2.33±0.14a
Arf6-T27N+TNF-α组 1.92±0.13b 1.83±0.15b
F值 138.330 97.516
P值 < 0.001 < 0.001
1
Gray JM, Rasanayagam S, Engel C, et al. State of the evidence 2017: an update on the connection between breast cancer and the environment[J]. Environ Health, 2017, 16(1):94.
2
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1):7-34.
3
Park S, Zhu J, Altan-Bonnet G, et al. Monocyte recruitment and activated inflammation are associated with thyroid carcinogenesis in a mouse model[J]. Am J Cancer Res, 2019, 9(7):1439-1453.
4
Cai T, Santi R, Tamanini I, et al. Current knowledge of the potential links between inflammation and prostate cancer[J]. Int J Mol Sci, 2019, 20(15):pii: E3833.
5
Bishayee A. The role of inflammation and liver cancer[J]. Adv Exp Med Biol, 2014, 816:401-435.
6
Shin SP, Kim NK, Kim JH, et al. Association between hepatocellular carcinoma and tumor necrosis factor alpha polymorphisms in South Korea[J]. World J Gastroenterol, 2015, 21(46):13064-13072.
7
Skrinjar I, Brailo V, Vidovic-Juras D, et al. Evaluation of pretreatment serum interleukin-6 and tumour necrosis factor alpha as a potential biomarker for recurrence in patients with oral squamous cell carcinoma[J]. Med Oral Patol Oral Cir Bucal, 2015, 20(4):e402-e407.
8
Sethi G, Sung B, Aggarwal BB. TNF: a master Switch for inflammation to cancer[J]. Front Biosci, 2008, 13:5094-5107.
9
Tian XY, Xu LM, Wang P. MiR-191 inhibits TNF-alpha induced apoptosis of ovarian endometriosis and endometrioid carcinoma cells by targeting DAPK1[J]. Int J ClinExpPathol, 2015, 8(5):4933-4942.
10
Ma Y, Ren Y, Dai ZJ, et al. IL-6, IL-8 and TNF-α levels correlate with disease stage in breast cancer patients[J]. Adv Clin Exp Med, 2017, 26(3):421-426.
11
Wu G, Niu M, Qin J, et al. Inactivation of Rab27B-dependent signaling pathway by calycosin inhibits migration and invasion of ER-negative breast cancer cells[J]. Gene, 2019, 709:48-55.
12
Liu G, Yan T, Li X, et al. Daam1 activates RhoA to regulate Wnt5a induced glioblastoma cell invasion[J]. Oncol Rep, 2018, 39(2): 465-472.
13
Hu Z, Du J, Yang L, et al. GEP100/Arf6 is required for epidermal growth factor-induced ERK/Rac1 signaling and cell migration in human hepatoma HepG2 cells[J]. PLoS One, 2012, 7(6):e38777.
14
Wauters L, Billiet T, Papamichael K, et al. Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatment[J]. Eur J Gastroenterol Hepatol, 2017, 29(1):84-90.
15
Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes[J]. Cell, 2003, 114(2):181-190.
16
Iocca HA, Isom HC. Tumor necrosis factor-alpha acts as a complete mitogen for primary rat hepatocytes[J]. Am J Pathol, 2003, 163(2):465-476.
17
Zidi I, Mestiri S, Bartegi A, et al. TNF-alpha and its inhibitors in cancer[J]. Med Oncol, 2010, 27(2):185-198.
18
Daniel D, Wilson NS. Tumor necrosis factor: Renaissance as a cancer therapeutic?[J]. Curr Cancer Drug Targets, 2008, 8(2):124-131.
19
Guo S, Messmer-Blust AF, Wu J, et al. Role of a20 in cIAP-2 protection against tumor necrosis factor α (TNF-α)-mediated apoptosis in endothelial cells[J]. Int J MolSci, 2014, 15(3):3816-3833.
20
Wang H, Liu J, Hu X, et al. Prognostic and therapeutic values of tumor necrosis Factor-Alpha in hepatocellular carcinoma[J]. Med SciMonit, 2016, 22:3694-3704.
21
Donaldson JG, Jackson CL. ARF family G proteins and their regulators: roles in membrane transport, development and disease[J]. Nat Rev Mol Cell Biol, 2011, 12(6):362-375.
22
Tanna CE, Goss LB, Ludwig CG, et al. Arf GAPs as regulators of the actin Cytoskeleton-An update[J]. Int J MolSci, 2019, 20(2):pii: E442.
23
Li R, Peng C, Zhang X, et al. Roles of Arf6 in cancer cell invasion, metastasis and proliferation[J]. Life Sci, 2017, 182:80-84.
24
Sabe H, Hashimoto S, Morishige M, et al. The EGFR-GEP100-Arf6-AMAP1 signaling pathway specific to breast cancer invasion and metastasis[J]. Traffic, 2009, 10(8):982-993.
25
Matsumoto Y, Sakurai H, Kogashiwa Y, et al. Inhibition of epithelial-mesenchymal transition by cetuximab via the EGFR-GEP100-Arf6-AMAP1 pathway in head and neck cancer[J]. Head Neck, 2017, 39(3): 476-485.
26
Marchesin V, Montagnac G, Chavrier P. ARF6 promotes the formation of Rac1 and WAVE-dependent ventral F-actin rosettes in breast cancer cells in response to epidermal growth factor[J]. PLoS One, 2015, 10(3):e0121747.
[1] 洪玮, 叶细容, 刘枝红, 杨银凤, 吕志红. 超声影像组学联合临床病理特征预测乳腺癌新辅助化疗完全病理缓解的价值[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(06): 571-579.
[2] 刘伟, 牛云峰, 安杰. LINC01232 通过miR-516a-5p/BCL9 轴促进三阴性乳腺癌的恶性进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 330-338.
[3] 周世振, 朱兴亚, 袁庆港, 刘理想, 王凯, 缪骥, 丁超, 汪灏, 管文贤. 吲哚菁绿荧光成像技术在腹腔镜直肠癌侧方淋巴结清扫中的应用效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 44-47.
[4] 黄一博, 李至彦, 林晨, 陶亮, 王萌, 管文贤. 胃癌根治术中淋巴结示踪剂的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 586-588.
[5] 韩婧, 郝少龙, 康骅. 北京市单中心甲状腺癌患者临床特征的回顾分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 490-493.
[6] 张钊, 骆成玉, 张树琦, 何平, 李旭斌. 不同术式治疗早期乳腺癌的效果及并发症发生率、复发率比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 494-497.
[7] 宋佳, 汪波, 孙凯律, 商江峰, 吴旦平, 肇毅. 吲哚菁绿荧光显影联合亚甲蓝染色在乳腺癌前哨淋巴结活检中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 498-501.
[8] 孙建娜, 孔令军, 任崇禧, 穆坤, 王晓蕊. 266例首诊Ⅳ期乳腺癌手术患者预后分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 502-505.
[9] 陆镜明, 韩大为, 任耀星, 黄天笑, 向俊西, 张谞丰, 吕毅, 王傅民. 基于术前影像组学的肝内胆管细胞癌淋巴结转移预测的系统性分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 852-858.
[10] 刘琦, 王守凯, 王帅, 苏雨晴, 马壮, 陈海军, 司丕蕾. 乳腺癌肿瘤内微生物组的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 841-845.
[11] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[12] 王帅, 张志远, 苏雨晴, 李雯雯, 王守凯, 刘琦, 李文涛. 孟德尔随机化及其在乳腺癌研究中的应用进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 671-676.
[13] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[14] 王曦娅, 尹弘青, 丁伟, 徐滨, 于海源, 马东升, 邵军. 桥本背景下甲状腺乳头状癌多参数分析预测大容量淋巴结转移[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 548-554.
[15] 张梦婷, 穷拉姆, 色珍, 李逸群, 德庆旺姆. 西藏地区藏族乳腺癌新辅助化疗的真实世界研究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 441-446.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号